Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: preliminary results.
OBJECTIVE
Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for local tumor control of primary and secondary malignancies of the liver. We report on our updated experience with SBRT in patients with non-resectable tumors of the liver.


METHODS
Our first 17 consecutive patients (mean age 58.1 years) receiving SBRT for HCC (n = 6), IHC (n = 3), and LM (n = 8) are presented. Mean radiation dose was 34 Gy delivered over 1-3 fractions.


RESULTS
Treated patients had a mean decrease in maximum pretreatment tumor diameter from 6.9 +/- 4.6 cm to 5.0 +/- 2.1 cm at three months after treatment (P < .05). The mean total tumor volume reduction was 44% at six months (P < .05). 82% of all patients (14/17) achieved local control with a median follow-up of 8 months. 100% of patients with HCC (n = 6) achieved local control. Patients with surgically placed fiducial markers had no complications related to marker placement.


CONCLUSIONS
Our preliminary results showed that SBRT is a safe and effective local treatment modality in selected patients with liver malignancies with minimal adverse events. Further studies are needed to define its role in the management of these malignancies.
Goyal
K
K
Department of Surgery, University Hospitals-Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Einstein
D
D
Yao
M
M
Kunos
C
C
Barton
F
F
Singh
D
D
Siegel
C
C
Stulberg
J
J
Sanabria
J
J
D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D016634:Radiosurgery; D016896:Treatment Outcome